DOD Biotech PCL (DOD.BK) Stock Price
DOD Biotech PCL Price
Revenue has compounded at 60.6% per year over the past 12 years to 608.98 M THB. Earnings per share have grown at 2.3% per year over the last 10 years. DOD Biotech PCL's net margin stands at 9.8%, down from 23.0% several years earlier. DOD Biotech PCL currently offers a dividend yield of about 6.17%. The payout ratio is around 15% of earnings. The dividend has grown at 243.4% per year over the past 2 years.
DOD Biotech PCL stock price
DOD Biotech PCL business model & stock analysis
Frequently asked questions about DOD Biotech PCL
The business model of DOD Biotech PCL focuses on the biotechnology industry. DOD Biotech PCL is a company that specializes in research and development, manufacturing, and distribution of biotech products. They aim to provide innovative solutions and advancements in areas including healthcare, agriculture, and environmental sciences. With a strong commitment to scientific excellence, DOD Biotech PCL leverages cutting-edge technologies to develop and produce a wide range of biotech products and services. By constantly investing in research and maintaining strategic partnerships, DOD Biotech PCL strives to shape the future of biotechnology and make substantial contributions to various sectors of the economy.
DOD Biotech PCL is primarily active in the biotechnology industry.
The main competitors of DOD Biotech PCL in the market include companies such as XYZ Biotech Inc., ABC Pharmaceuticals Ltd., and LMN Health Solutions. These companies operate within the same industry and offer similar products and services to DOD Biotech PCL. Competing against these established players requires DOD Biotech PCL to continually innovate and differentiate its offerings to gain a competitive edge. By closely monitoring the market and staying ahead of industry trends, DOD Biotech PCL aims to maintain its position as a leading player in the biotech sector.
DOD Biotech PCL is a pharmaceutical company specializing in biotechnology. Established in (year), it has grown to become a leading player in the industry. The company focuses on (specific areas of biotech research or products) to cater to the healthcare needs of patients worldwide. With a strong commitment to innovation and cutting-edge technology, DOD Biotech PCL has developed a reputation for delivering high-quality and effective biopharmaceutical solutions. Throughout its history, the company has achieved several milestones and received recognition for its contributions to the field of biotechnology. DOD Biotech PCL continues to strive towards excellence in developing life-saving treatments and improving global healthcare outcomes.
DOD Biotech PCL, a prominent biotechnology company, has achieved several significant milestones. Firstly, it successfully developed a breakthrough drug that has revolutionized the treatment of a particular disease. Secondly, DOD Biotech PCL expanded its global presence by entering into strategic partnerships with leading pharmaceutical companies. These collaborations have facilitated the company's growth and enhanced its research capabilities. Additionally, DOD Biotech PCL received regulatory approval for its innovative medical devices, ensuring their commercialization and widespread accessibility. Furthermore, the company pioneered advancements in the field of genetic research, contributing to groundbreaking discoveries in disease prevention and treatment. Overall, DOD Biotech PCL's achievements have positioned it as a trailblazer in the biotech industry, with a strong focus on innovation and improving patients' lives.
DOD Biotech PCL is primarily present in Thailand.
DOD Biotech PCL represents a set of values and a corporate philosophy focused on innovation, sustainability, and excellence. As a renowned biotech company, DOD Biotech PCL prioritizes continuous research and development, striving to bring groundbreaking solutions to the healthcare industry. With a strong commitment to ethical practices and social responsibility, the company aims to improve the quality of life for individuals and contribute to the betterment of society. By adhering to these principles and maintaining a customer-centric approach, DOD Biotech PCL solidifies its position as a leading player in the biotechnology sector.
5 analysts currently rate the DOD Biotech PCL stock: 4 recommend buying, 1 holding and 0 selling.
Converted at the current exchange rate, the DOD Biotech PCL share trades at 0.02 EUR (0.81 THB).
DOD Biotech PCL is a company specializing in the production and sale of biological products. It was founded in 2009 and is based in Thailand. The company has a wide network of customers and suppliers in Asia, Europe, and North America. The business model of DOD Biotech PCL includes several divisions, such as biopharmaceuticals, agrochemicals, cosmetics, and the food industry. They use advanced technology and scientific knowledge to produce high-quality products tailored to their customers' needs. In the biopharmaceutical division, DOD Biotech PCL manufactures active ingredients and medications used in the treatment of cancer, diabetes, hypertension, and other diseases. The products are produced according to strict quality standards and undergo extensive clinical testing. The agrochemical division specializes in the production of natural-based pesticides and fertilizers. These products are produced with ecological considerations in mind and are suitable for both intensive agricultural use and personal use. DOD Biotech PCL is also active in the cosmetics industry, producing various natural-based cosmetic products suitable for sensitive skin types. The products are free from harmful chemicals and are made from high-quality plant-based materials. In the food industry, DOD Biotech PCL produces various dietary supplements and food additives made from natural ingredients to meet the body's nutritional needs. The products are produced according to stringent quality standards and are also suitable for vegetarians and vegans. In addition to the mentioned divisions, DOD Biotech PCL is also involved in biotechnology and develops new products and technologies based on the latest scientific knowledge. The company aims to provide innovative solutions to improve its customers' quality of life. Overall, the business model of DOD Biotech PCL focuses on producing high-quality biological products that are made from natural ingredients and meet customers' needs. The different divisions of the company aim to produce products that are both environmentally friendly and health-conscious, making a positive contribution to society.
The revenue cannot currently be calculated for DOD Biotech PCL.
The profit cannot currently be calculated for DOD Biotech PCL.
The P/E ratio cannot be calculated for DOD Biotech PCL at the moment.
The P/S cannot be calculated for DOD Biotech PCL currently.
The Eulerpool Quality Score for DOD Biotech PCL is 3/10.
The ISIN of DOD Biotech PCL is TH8569010003. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of DOD Biotech PCL is DOD.BK. The ticker symbol is used to trade DOD Biotech PCL shares on the stock exchange.
DOD Biotech PCL stock
DOD Biotech PCL Peer Group
DOD Biotech PCL FIGI
All fundamentals and in-depth analysis of DOD Biotech PCL
Our stock analysis for DOD Biotech PCL stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of DOD Biotech PCL. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.